Combination therapy aiming at additional MM targets (such as CD38, CD24, CD138, SLAMF7, and GPRC5D) may be a better CAR-T treatment strategy to overcome the heterogeneity of MM and avoid clonal selection based on the loss of one specific antigen. This evidence concerns the gene SDC1 and Miyoshi myopathy.